Sherif I Badawy

US Patent:

20050059719, Mar 17, 2005

Filed:

Aug 23, 2004

Appl. No.:

10/924043

Inventors:

Sherif Badawy - Dayton NJ, US
Munir Hussain - Belle Mead NJ, US
Duxin Sun - Dublin OH, US

International Classification:

A61K031/42

US Classification:

514379000

Abstract:

An oral solid dosage formulation is provided which contains a Factor Xa inhibitor for which oral bioavailability is not reduced by co-administration of antacids, H2 antagonists and proton pump inhibitors. Such solid dosage formulation includes the Factor Xa inhibitor of the structure, a pharmaceutically acceptable carrier, and an acid component, such as tartaric acid, whereby upon ingestion of the oral solid dosage formulation, the acid component increases solubility of the Factor Xa inhibitor in the local environment of the dissolving solid dosage formulation resulting in an otherwise lower degree of supersaturation of the Factor Xa inhibitor in such environment, than if the acid were not present. The result is that precipitation of the Factor Xa inhibitor in the form of its insoluble free base is minimized during dissolution of the Factor Xa inhibitor thereby increasing its oral bioavailability. A method for enhancing bioavailability of the Factor Xa inhibitor is also provided wherein an acid such as tartaric acid is incorporated with the solid dosage pharmaceutical carrier for the Factor Xa inhibitor.

Address:

13 Tulip Dr, Dayton, NJ 08810

Phone:

732 329-0871

VIN:

4T1BK46K87U039548

Make:

TOYOTA

Model:

CAMRY

Year:

2007